SPARC Reports Q3 FY26 Net Loss of ₹80.57 Crores, Revenue Drops to ₹8.45 Crores
Sun Pharma Advanced Research Company Limited reported continued losses in Q3 FY26 with net loss of ₹80.57 crores and revenue declining to ₹8.45 crores. The company fulfilled regulatory disclosure requirements by publishing financial results in newspapers and recognized exceptional costs related to India's new labour codes.
*this image is generated using AI for illustrative purposes only.
Sun Pharma Advanced Research Company Limited (SPARC) announced its unaudited standalone and consolidated financial results for the third quarter ended December 31, 2025, showing continued losses amid declining revenue. The Board of Directors approved these results at their meeting held on February 09, 2026.
Financial Performance Overview
The company reported significant financial challenges during the quarter, with both standalone and consolidated operations showing substantial losses.
| Metric (₹ Crores): | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Revenue from Operations: | 8.45 | 14.91 | -43.30% |
| Total Income: | 8.45 | 15.10 | -44.04% |
| Net Loss (Standalone): | 80.57 | 79.71 | -1.08% |
| Net Loss (Consolidated): | 80.42 | 79.51 | -1.15% |
| Loss Per Share (₹): | 2.48 | 2.46 | -0.81% |
Nine-Month Performance Analysis
For the nine months ended December 31, 2025, SPARC's financial performance showed mixed results with reduced losses but lower revenue.
| Parameter (₹ Crores): | 9M FY26 | 9M FY25 | Variance |
|---|---|---|---|
| Revenue from Operations: | 25.95 | 44.56 | -41.77% |
| Total Income: | 35.10 | 46.37 | -24.31% |
| Net Loss (Consolidated): | 208.14 | 282.74 | +26.38% |
| Loss Per Share (₹): | 6.41 | 8.71 | +26.41% |
Regulatory Compliance and Disclosures
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published extracts of its financial results in Financial Express (English Newspaper) all editions and Financial Express (Gujarati Newspaper) Ahmedabad Edition on February 10, 2026. The complete financial results are available on the company's website at https://sparc.life/ and on the stock exchange websites.
Exceptional Items and Regulatory Impact
The company recognized an exceptional item of ₹12.36 crores during Q3 FY26 related to India's new labour codes. The Government of India consolidated 29 existing labour legislations into four unified codes: Code on Wages 2019, Code on Social Security 2020, Industrial Relations Code 2020, and Occupational Safety, Health and Working Conditions Code 2020. These codes became effective from November 21, 2025, introducing changes including uniform wage definitions and impacting employee benefits such as gratuity and leave encashment.
Expense Structure
The company's major expense categories for Q3 FY26 included:
- Employee benefits expense: ₹26.90 crores (standalone)
- Professional charges: ₹15.95 crores (standalone)
- Cost of materials consumed: ₹7.21 crores
- Clinical trial expenses: ₹6.27 crores
- Finance costs: ₹6.78 crores
Recent Regulatory Approval
On February 03, 2026, the United States Food and Drug Administration granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®. The PRV is a tradeable voucher that can be redeemed for priority review of subsequent drug applications.
Going Concern Status
Despite incurring cash losses in current and past quarters, the company maintains its going concern status based on a support letter from its promoter group entity. SPARC operates in a single reportable business segment of pharmaceutical research and development.
Historical Stock Returns for Sun Pharma Advanced Research Co
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.10% | -3.48% | -11.61% | -14.49% | -0.51% | -27.04% |
19
